Pliant Therapeutics Receivables 2019-2025 | PLRX

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pliant Therapeutics receivables from 2019 to 2025. Receivables can be defined as the total amount of collectibles for a company

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Pliant Therapeutics receivables from 2019 to 2025. Receivables can be defined as the total amount of collectibles for a company

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$218.6B
Amgen (AMGN)	$164.4B
Gilead Sciences (GILD)	$137B
Vertex Pharmaceuticals (VRTX)	$120.7B
Bristol Myers Squibb (BMY)	$97.7B
CSL (CSLLY)	$84.2B
GSK (GSK)	$75.8B
Regeneron Pharmaceuticals (REGN)	$60.6B
Alnylam Pharmaceuticals (ALNY)	$42.4B
Argenex SE (ARGX)	$35B
BioNTech SE (BNTX)	$26.8B
Royalty Pharma (RPRX)	$20.3B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$16.2B
Genmab (GMAB)	$14B
Genmab (GNMSF)	$13.8B
Incyte (INCY)	$13.3B
Moderna (MRNA)	$12.7B
Exelixis (EXEL)	$12.1B
BioMarin Pharmaceutical (BMRN)	$11.4B
QIAGEN (QGEN)	$11B
Swedish Orphan Biovitrum (BIOVF)	$10.6B
Ascendis Pharma (ASND)	$10.1B
Exact Sciences (EXAS)	$9.4B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.3B
Bio-Techne Corp (TECH)	$8.3B
Legend Biotech (LEGN)	$8.1B
Roivant Sciences (ROIV)	$7.8B